Alex­ion chief reg­is­ters $16.5M in pay af­ter a sol­id year, with a rel­a­tive­ly low 74-to-1 ra­tio com­pared to a well paid ...

7 years ago
People

Is­raeli biotech flunks PhII liv­er can­cer study, but it in­sists drug Can-Fite dis­ease in sub­set of pa­tients

7 years ago
R&D

The top 10 Alzheimer's deals tell us a lot about a big change of di­rec­tion for a dis­as­ter-prone field

7 years ago
R&D
Pharma

FTC de­mands more in­fo from Bris­tol-My­ers, Cel­gene on pso­ri­a­sis drugs, sig­nal­ing a po­ten­tial hitch for $74B deal

7 years ago
Deals
Pharma

Da­ta sug­gest US, UK uni­ver­si­ties fall woe­ful­ly short on re­port­ing clin­i­cal tri­al re­sults

7 years ago
R&D

Con­tend­ing for CD47 throne, Arch On­col­o­gy scores $50M as it ramps up PhI stud­ies

7 years ago
Financing

Buy­out vote loom­ing, Cel­gene files for ozan­i­mod OK (again), with a multi­bil­lion-dol­lar bet rid­ing on every step

7 years ago
Financing
Deals

Biotech’s new­born uni­corn Sana grabs Har­vard tech aimed at slip­ping en­gi­neered stem cells past the im­mune sys­tem

7 years ago
Startups

Pro­teosta­sis shares shat­tered as weak triplet da­ta in­spires a scorch­ing back­lash

7 years ago
R&D

Aim­mune's peanut al­ler­gy im­munother­a­py clears Eu­ro­pean PhI­II with fly­ing col­ors, paving way for first US, EU ...

7 years ago
R&D
Pharma

J&J, Bay­er agree to $775M pay­out to set­tle Xarel­to lit­i­ga­tion; Bio­gen launch­es $5B buy­back in the wake of a dis­as­ter; ...

7 years ago
News Briefing

Avanir cites 'en­cour­ag­ing' progress in PhI­II pro­gram for Alzheimer's ag­i­ta­tion

7 years ago
R&D

Hu­malog's list price may have gone up, but Lil­ly says it got paid less per sale in 2018 ver­sus 2014

7 years ago
Pharma

Price hikes, a strate­gic re­treat and 1 big new ap­proval has shak­en up the rank­ings of the 20 most ex­pen­sive drugs on ...

7 years ago
Pharma

Af­ter ovar­i­an can­cer flop, Phar­ma­Mar's lur­binecte­din makes the cut in small cell lung can­cer

7 years ago
R&D

Ther­mo Fish­er forges $1.7 bil­lion deal to buy a con­tract play­er in the boom­ing gene ther­a­py field

7 years ago
Deals

Is a se­vere­ly dam­aged Bio­gen look­ing to shed its ties to a con­tro­ver­sial de­vel­op­ment part­ner?

7 years ago
Deals
R&D

Al­ler­gan chief Brent Saun­ders bows to ac­tivists, but Ap­paloosa blasts back that it's all too lit­tle, too late

7 years ago
People
Deals

FDA snubs Sanofi, Lex­i­con on their pitch for SGLT1/2 di­a­betes drug so­tagliflozin, com­pa­nies mum on what went wrong

7 years ago
Pharma

En­tra­da picks Syn­tim­mune vet Mario Saltarel­lo as CMO; Gene ther­a­py mak­er Or­chard hires Ran Zheng as CTO

7 years ago
Peer Review

Hack­ing in­to macrophage at­tack cir­cuits, Stan­ford sci­en­tists pitch a bet­ter ear­ly-warn­ing alert sys­tem for tu­mors

7 years ago
Discovery

No­var­tis' Al­con unit set for Swiss/NYSE de­but on April 9; Novo's keen­ly an­tic­i­pat­ed oral GLP-1 sub­mit­ted for speedy ...

7 years ago
News Briefing

Bone-mar­row fo­cused Ima­go Bio­Sciences scores $40M in Omega-led round

7 years ago
Financing
Startups

Af­ter land­ing a his­toric FDA OK, Al­ny­lam chief John Maraganore scores a big raise

7 years ago
People
First page Previous page 964965966967968969970 Next page Last page
A service from the Financial Times